公开(公告)号：US20250095390A1

公开(公告)日：2025-03-20

申请号：US18662788

申请日：2024-05-13

Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services

Inventor： Kapil Bharti ,  Nathan A. Hotaling ,  Nicholas J. Schaub ,  Carl G. Simon

IPC: G06V20/69 ,  G06F18/214 ,  G06T7/00 ,  G06V10/82

Abstract: A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.

公开(公告)号：US12233124B2

公开(公告)日：2025-02-25

申请号：US18462340

申请日：2023-09-06

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Institute For Research in Biomedicine

Inventor： Peter Kwong ,  Michael Gordon Joyce ,  Baoshan Zhang ,  Yongping Yang ,  Peter Collins ,  Ursula Buchholz ,  Davide Corti ,  Antonio Lanzavecchia ,  Guillaume Stewart-Jones

IPC: C07K14/115 ,  A61K39/155 ,  A61K39/39 ,  A61K48/00 ,  C07K14/005 ,  C07K14/135

Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

公开(公告)号：US20250026723A1

公开(公告)日：2025-01-23

申请号：US18709949

申请日：2022-12-08

Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human

Inventor： Malliga R. Iyer ,  George Kunos ,  Resat Cinar

IPC: C07D231/06 ,  C07D211/96

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to sulfur- and selenium-containing compounds that act as agonists and/or antagonists of cannabinoid receptors, methods of making same, pharmaceutical compositions comprising the same, and methods of treating metabolic disorders, psychiatric disorders, neurological disorders, pain disorders, gastrointestinal disorders, cancers, inflammation-related disorders, substance abuse associated pathologies, and other conditions using the same.

公开(公告)号：US12201658B2

公开(公告)日：2025-01-21

申请号：US17033166

申请日：2020-09-25

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Charles P. Venditti ,  Randy Chandler ,  William J. Pavan

IPC: A61K35/761 ,  A61K48/00 ,  A61P3/00 ,  A61P25/28 ,  C07K14/075 ,  C12N7/04 ,  C12N15/86 ,  C12N15/861

Abstract: Provided herein are compositions and methods for the viral gene therapy (e.g., AAV-directed gene therapy) of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.

公开(公告)号：US20250011406A1

公开(公告)日：2025-01-09

申请号：US18707305

申请日：2022-11-04

Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC ,  The General Hospital Corporation

Inventor： Young Do Kwon ,  Amarendra Pegu ,  Eun Sung Yang ,  Peter Kwong ,  Robert Seder ,  Facundo Batista ,  Sven Kratochvil ,  Chen-Hsiang Shen ,  Reda Rawi ,  Mateo Reveiz ,  Prabhanshu Tripathi

IPC: C07K16/20 ,  A61K39/00 ,  A61P33/02

Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.

公开(公告)号：US12172038B2

公开(公告)日：2024-12-24

申请号：US18194105

申请日：2023-03-31

Applicant: AbCellera Biologics Inc. ,  The United States of America, as represented by the Secretary, Department of Health and Human Svcs.

Inventor： Kathryn Westendorf ,  Stefanie Zentelis ,  Krithika Muthuraman ,  Kevin Jepson ,  Ester Falconer ,  John Mascola ,  Barney Graham ,  Kizzmekia Corbett ,  Julie Ledgerwood ,  Lingshu Wang ,  Olubukola Abiona ,  Wei Shi ,  Wing-pui Kong ,  Yi Zhang ,  Bryan Edward Jones ,  Denisa Foster ,  Julian Davies ,  Qing Chai ,  Christopher Carl Frye ,  Ganapathy Gopalrathnam ,  Jörg Hendle ,  John Michael Sauder ,  Jeffrey Streetman Boyles ,  Anna Pustilnik

IPC: A61P11/00 ,  A61K39/00 ,  A61K39/215 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26 ,  A61K47/68 ,  A61P31/14 ,  C07K16/10 ,  G01N33/50 ,  G01N33/569

Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

公开(公告)号：US20240409948A1

公开(公告)日：2024-12-12

申请号：US18816498

申请日：2024-08-27

Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services

Inventor： Charles P. Venditti ,  William J. Pavan ,  Randy J. Chandler

IPC: C12N15/67 ,  C12N15/52 ,  C12N15/62 ,  C12N15/86

Abstract: The present disclosure provides compositions for viral gene therapy, e.g. Adeno-Associated virus-directed gene therapy, and methods of using the same for the treatment and/or prevention of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.

公开(公告)号：US20240382614A1

公开(公告)日：2024-11-21

申请号：US18570579

申请日：2022-06-16

Applicant: Barinthus Biotherapeutics North America, Inc. ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC

Inventor： Geoffrey M. Lynn ,  Yaling Zhu ,  Sarah R. Nichols ,  Qiuyin Ren ,  Andrew S. Ishizuka

IPC: A61K47/69 ,  A61K45/06 ,  A61K47/60 ,  A61K47/61 ,  A61P37/06

Abstract: The present disclosure relates to a composition comprising a first amphiphile and optionally a second amphiphile each having the formula S-[B]-[U]-H-[D] and at least one drug molecule is noncovalently associated with or covalently bonded directly or via a suitable linker X1 to the first amphiphile and/or to the optional second amphiphile. The composition is useful in treating a cancer, an infectious disease or an inflammatory disease.

公开(公告)号：US12145922B2

公开(公告)日：2024-11-19

申请号：US18111241

申请日：2023-02-17

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services ,  The University of Kansas ,  The University of North Carolina at Chapel Hill

Inventor： David R. Sibley ,  Amy Elizabeth Moritz ,  R. Benjamin Free ,  Joseph P. Steiner ,  Noel Terrence Southall ,  Marc Ferrer ,  Xin Hu ,  Warren S. Weiner ,  Jeffrey Aubé ,  Kevin Frankowski

IPC: C07D401/12 ,  A61P25/28 ,  C07D209/42 ,  C07D213/65 ,  C07D213/81 ,  C07D235/24 ,  C07D295/185 ,  C07D307/85 ,  C07D317/64 ,  C07D333/70 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04

Abstract: The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.

公开(公告)号：US20240316056A1

公开(公告)日：2024-09-26

申请号：US18735506

申请日：2024-06-06

Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services ,  University of Kansas ,  Northwestern University

Inventor： Udo Rudloff ,  Serguei Kozlov ,  Juan Jose Marugan ,  Sui Huang ,  Samarjit Patnaik ,  John C. Braisted ,  Noel T. Southall ,  Marc Ferrer ,  Christopher Dextras ,  John Haslam ,  Michael Baltezor

IPC: A61K31/519 ,  A61K31/7068 ,  A61K45/06 ,  A61K47/12 ,  A61P35/04

CPC classification number: A61K31/519 ,  A61K31/7068 ,  A61K45/06 ,  A61K47/12 ,  A61P35/04

Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I):




in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.